Citizens Reiterates Market Outperform on Bicara Therapeutics, Maintains $31 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
Citizens analyst Reni J. Benjamin reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Market Outperform and maintains $31 price target.
Citizens analyst Reni J. Benjamin reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Market Outperform and maintains $31 price target.